1 / 39

OST 529 Systems Biology: Endocrinology

OST 529 Systems Biology: Endocrinology. Keith Lookingland Associate Professor Dept. Pharmacology & Toxicology. Adrenocorticosteroids. Goodman & Gilman’s “The Pharmacological Basis of Therapeutics” 10th Edition Chapter 60: 1649-1677. Hormone Negative Feedback Hypothalamic-Pituitary Systems.

Olivia
Télécharger la présentation

OST 529 Systems Biology: Endocrinology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. OST 529 Systems Biology: Endocrinology Keith Lookingland Associate Professor Dept. Pharmacology & Toxicology

  2. Adrenocorticosteroids Goodman & Gilman’s “The Pharmacological Basis of Therapeutics” 10th Edition Chapter 60: 1649-1677

  3. Hormone Negative Feedback Hypothalamic-Pituitary Systems • Thyroid Axis (Thyroid Hormones) • Adrenocortical Axis (Glucocorticoids) • Ovarian Axis (Estrogen/Progesterone) • Testicular Axis (Testosterone)

  4. Peripheral Substrate Systems • Glucose - Insulin/Glucagon • Sodium/Potassium - Aldosterone • Calcium - PTH/Calcitonin/Vitamin D

  5. Adrenocorticosteroids • Glucocorticoids + Mineralocorticoids • Synthesis and metabolism • Secretion • Actions • Adrenocortical Insufficiency • Addison’s disease (primary & secondary) • Adrenocortical Hyperactivity • Congenital adrenal hyperplasia • Cushing’s disease • Conn’s syndrome (primary aldosteronism)

  6. Adrenal Gland

  7. Adrenocorticosteroids

  8. Glucocorticoids

  9. Transport of Cortisol • 95% bound to corticosteroid binding globulin (CBG) • 5% free, bioactive • cortisol half-life (90-110 min)

  10. Metabolism of Cortisol

  11. Hypothalamic-Pituitary-Adrenal (HPA) Axis

  12. Circadian Rhythm of Cortisol Secretion

  13. Mechanism of Glucocorticoid Action

  14. Physiological Actions of Glucocorticoids • Metabolic Glucose Availability for the Brain • Anti-inflammatory • Immunosuppression

  15. Metabolic Actions of Cortisol

  16. Anti-inflammatory Actions of Cortisol • phagocytic cell function pyrogens,elastase,collagenase • reduces edema capillary permeability arteriole vasoconstriction • blocks basophil histamine

  17. Immunosuppressive Actions of Cortisol

  18. Mineralocorticoids

  19. Transport and Metabolism of Aldosterone • weakly bound to plasma proteins • 95% free, bioactive • aldosterone half-life (20-30 min) • degraded in liver, secreted in urine as a water soluble conjugate

  20. Control of Aldosterone Secretion

  21. Mechanisms of Aldosterone Action

  22. Adrenocortical Insufficiency • Primary (Addison’s Disease) • hyposecretion of both cortisol & aldosterone • hypersecretion of ACTH (loss of negative feedback) • glucocorticoid insufficiency • weakness, fatigue • inability to maintain fasting plasma glucose • mineralocorticoid insufficiency • sodium loss, potassium retention • dehydration • Secondary • defect in hypothalamic-pituitary axis • hyposecretion of ACTH and cortisol

  23. Synthetic Glucocorticoids • Cortisol • short-acting • orally active • glucocorticoid replacement adrenal insufficiency • Triamcinolone • intermediate-acting • topical • localized allergic and arthritic disorders • Dexamethasone • long-acting • diagnostic • Dexamethasone Suppression Test

  24. Side Effects of Glucocorticoid Therapy

  25. Synthetic Mineralocorticoids

  26. Synthetic Mineralocorticoids Fludrocortisone • oral, injectable, topical compilations • mimics aldosterone action • sodium retention • potassium excretion • mineralocorticoid replacement adrenal insufficiency

  27. Adrenocortical Hyperactivity • Congenital Adrenal Hyperplasia • primary defect in cortisol biosynthetic enzymes • 21-B hydroxylase • shunts precursors into androgen pathway • compensatory increase in ACTH (loss of negative feedback) • adrenal hypertrophy • virilization of physical features • im cortisone/dexamethasome to suppress ACTH • oral cortisol

  28. Adrenocortical Hyperactivity • Cushing’s Syndrome • adrenal hyperplasia • secondary to ACTH-secreting pituitary or ectopic tumor • loss of negative feedback unresponsive to low dose dexamethasone

  29. Adrenocortical Hyperactivity • Cushing’s Syndrome • excessive glucocorticoid activity • muscle atrophy, thinning of skin (protein catabolism) • facial & truncal obesity (lipid deposition insulin-dependent adipocytes) • poor wound healing (immunosuppression) • surgical removal of tumor (oral cortisol) • adrenalectomy (oral cortisol & fludrocortisone)

  30. Adrenocortical Hyperactivity • Primary Aldosteronism (Conn’s Syndrome) • aldosterone-secreting adrenal adenoma • excessive mineralocorticoid activity (electrolyte imbalance) • hypertension (sodium retention) • muscle weakness, tetany (potassium excretion) • adrenalectomy (oral cortisol & fludrocortisone) • spironolactone • aldosterone receptor antagonist • genomic actions (slow onset of action)

More Related